On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA). HG381 for
#Medicilon will exhibit the 2021 AACR Virtual Annual Meeting from April 10-15. Please visit our virtual booth for more information on our oncology and preclinical
Livzon Pharmaceutical Group Inc. (Livzon) obtained a “novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No.
Shanghai Medicilon Inc.
Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China